Skip to main content
    A

    Amphastar P (AMPH)

    Official site

    HEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NASDAQ

    $29.17
    -0.20 (-0.68%)

    Market Cap: $1.25B

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Amphastar P (AMPH) Earnings: Report Dates and Results

    Updated Nov 5, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    Amphastar P (AMPH) is expected to report earnings on Feb 24, 2027. In the quarter ended Sep 30, 2026, Amphastar P reported EPS of $1.01, above the $0.80 estimate. It beat the EPS estimate in 5 of the last 8 quarters.

    Earnings

    Performance (10Y)

    Beat Rate
    75%(30/40)
    Avg Surprise
    +40.20%
    Streak
    2 Q

    Upcoming Estimates

    Reports Feb 24, 2027 (est.)Period ending Dec 31, 2026
    EPS Consensus$0.79
    Range$0.51 - $1.05
    9 analysts
    Revenue Consensus
    $199.65M
    Range$179.34M - $214.20M
    8 analysts
    Reports May 5, 2027 (est.)Period ending Mar 31, 2027
    EPS Consensus$0.72
    Range$0.54 - $0.91
    4 analysts
    EPS Revisions
    3
    1
    30d
    EPS Estimate DriftChange to current
    90d ago$0.66+9.2%
    60d ago$0.71+1.1%
    30d ago$0.71+1.1%
    7d ago$0.71+1.1%
    Current$0.72
    Revenue Consensus
    $186.56M
    Range$170.00M - $203.00M
    3 analysts

    Next Report

    AMPH has an expected report date of Feb 24, 2027. Analysts' consensus for the quarter ending Dec 31, 2026 is 29.5% above the $0.61 reported for the quarter ended Dec 31, 2025.

    AMPH Earnings Call

    The latest AMPH earnings call transcript on file is labeled 2026Q3.

    Read the 2026Q3 transcript

    Earnings History

    Of the 40 quarters below that had an estimate, AMPH beat 30, missed 9 and matched 1. Revenue for the quarter ended Sep 30, 2026 was $207.61M, up 8.2% from $191.84M a year earlier.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Sep 30, 2026$1.01$0.80$0.70 - $1.05+26.25%Beat+8.6%70 up, 1 downNov 5, 2026$207.61M
    Jun 30, 2026$0.80$0.51$0.42 - $0.74+56.86%Beat+6.7%70 up, 3 downAug 6, 2026$183.90M
    Mar 31, 2026$0.42$0.71$0.54 - $0.78-40.85%Miss-43.2%71 up, 2 downMay 7, 2026$171.17M
    Dec 31, 2025$0.61$0.89$0.80 - $0.99-31.46%Miss-33.7%60 up, 1 downFeb 26, 2026$183.10M
    Sep 30, 2025$0.93$0.83$0.65 - $0.97+12.05%Beat-3.1%61 up, 3 downNov 6, 2025$191.84M
    Jun 30, 2025$0.75$0.64$0.61 - $0.82+17.19%Beat-20.2%61 up, 1 downAug 7, 2025$174.41M
    Mar 31, 2025$0.74$0.69$0.58 - $0.76+7.25%Beat-28.8%61 up, 0 downMay 7, 2025$170.53M
    Dec 31, 2024$0.92$0.94$0.87 - $1.16-1.95%Miss+4.5%62 up, 2 downFeb 27, 2025$186.52M
    Sep 30, 2024$0.96$0.98$0.89 - $1.13-2.04%Miss-16.5%50 up, 0 downNov 6, 2024$191.21M
    Jun 30, 2024$0.94$0.75$0.71 - $0.89+25.33%Beat+44.6%60 up, 0 downAug 7, 2024$182.39M
    Mar 31, 2024$1.04$0.79$0.74 - $1.04+31.65%Beat+67.7%65 up, 0 downMay 8, 2024$171.84M
    Dec 31, 2023$0.88$0.91$0.75 - $1.00-3.30%Miss+20.5%50 up, 0 downFeb 28, 2024$178.10M
    Sep 30, 2023$1.15$0.69$0.58 - $0.82+66.67%Beat+202.6%40 up, 0 downNov 8, 2023$180.56M
    Jun 30, 2023$0.65$0.56$0.52 - $0.62+16.07%Beat+66.7%41 up, 0 downAug 8, 2023$145.71M
    Mar 31, 2023$0.62$0.50$0.43 - $0.54+24.00%Beat+31.9%50 up, 0 downMay 9, 2023$140.02M
    Dec 31, 2022$0.73$0.41$0.37 - $0.44+78.05%Beat+73.8%50 up, 0 downFeb 28, 2023$135.02M
    Sep 30, 2022$0.38$0.39$0.35 - $0.42-2.56%Miss-17.4%60 up, 0 downNov 7, 2022$120.13M
    Jun 30, 2022$0.39$0.35$0.30 - $0.40+11.43%Beat+85.7%50 up, 0 downAug 8, 2022$123.47M
    Mar 31, 2022$0.47$0.36$0.29 - $0.39+30.56%Beat+74.1%61 up, 0 downMay 9, 2022$120.37M
    Dec 31, 2021$0.42$0.36$0.33 - $0.51+16.67%Beat+162.5%60 up, 0 downMar 10, 2022$120.89M
    Sep 30, 2021$0.46$0.23$0.22 - $0.29+100.00%Beat+206.7%6N/ANov 8, 2021$112.20M
    Jun 30, 2021$0.21$0.21$0.17 - $0.280.00%In line+31.2%6N/AAug 9, 2021$101.66M
    Mar 31, 2021$0.27$0.18$0.15 - $0.25+50.00%Beat+58.8%7N/AMay 6, 2021$103.02M
    Dec 31, 2020$0.16$0.14$0.12 - $0.15+14.29%Beat+128.6%7N/AMar 15, 2021$95.92M
    Sep 30, 2020$0.15$0.14$0.12 - $0.17+7.14%Beat+50.0%7N/ANov 6, 2020$83.43M
    Jun 30, 2020$0.16$0.14$0.10 - $0.20+14.29%Beat+100.0%7N/AAug 6, 2020$85.81M
    Mar 31, 2020$0.17$0.09$0.07 - $0.12+88.89%Beat+70.0%6N/AMay 7, 2020$84.69M
    Dec 31, 2019$0.07$0.08-$0.01 - $0.13-12.50%Miss-46.2%6N/AMar 12, 2020$83.38M
    Sep 30, 2019$0.10$0.07$0.03 - $0.11+42.86%Beat-16.7%6N/ANov 7, 2019$80.14M
    Jun 30, 2019$0.08$0.05-$0.05 - $0.08+60.00%Beat+166.7%6N/AAug 7, 2019$79.05M
    Mar 31, 2019$0.10$0.05-$0.03 - $0.07+100.00%BeatN/A6N/AMay 9, 2019$79.79M
    Dec 31, 2018$0.13$0.11$0.08 - $0.14+18.18%Beat+30.0%6N/AMar 12, 2019$89.69M
    Sep 30, 2018$0.12$0.11$0.02 - $0.21+9.09%Beat+71.4%6N/ANov 8, 2018$75.54M
    Jun 30, 2018$0.03$0.08$0.02 - $0.10-62.50%Miss-72.7%6N/AAug 8, 2018$71.04M
    Mar 31, 2018-$0.05$0.08$0.04 - $0.12-162.50%Miss-155.6%6N/AMay 9, 2018$58.39M
    Dec 31, 2017$0.10-$0.02-$0.30 - $0.10+600.00%Beat+900.0%6N/AMar 12, 2018$60.40M
    Sep 30, 2017$0.07$0.03N/A+133.33%Beat-50.0%N/AN/ANov 8, 2017$57.92M
    Jun 30, 2017$0.11$0.07N/A+57.14%Beat-52.2%N/AN/AAug 9, 2017$65.19M
    Mar 31, 2017$0.09$0.08N/A+12.50%Beat-25.0%N/AN/AMay 8, 2017$56.67M
    Dec 31, 2016$0.01-$0.01N/A+200.00%Beat-94.7%N/AN/AMar 13, 2017$63.54M
    Last 40 quarters

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was $3.03, down 21.5% from the year before. It was $0.50 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025$3.03-21.5%
    Dec 31, 2024$3.86+17.0%
    Dec 31, 2023$3.30+67.5%
    Dec 31, 2022$1.97+44.9%
    Dec 31, 2021$1.36+112.5%
    Dec 31, 2020$0.64+82.9%
    Dec 31, 2019$0.35+52.2%
    Dec 31, 2018$0.23-37.8%
    Dec 31, 2017$0.37-26.0%
    Dec 31, 2016$0.50N/A

    Earnings Calls

    The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 4,600 words across 11 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2026Q3Sep 30, 20264,60011
    2026Q2Jun 30, 20264,01010
    2026Q1Mar 31, 20263,2898
    2025Q4Dec 31, 20253,3818
    2025Q3Sep 30, 20253,67810
    2025Q2Jun 30, 20252,7559
    2025Q1Mar 31, 20254,2509
    2024Q4Dec 31, 20243,2869

    2026Q3 Earnings Call

    Opening remarks

    Dan Dischner Senior Vice President of Corporate Communications Thank you, Paul. Good afternoon, everyone, and thank you for joining Amphastar's third quarter 2026 earnings call. Earlier today, we reported our financial results for the third quarter ended September 30th, 2026, which are available on the Investors page of our website. The third quarter was marked by record commercial performance, continued progress on our IMS remediation efforts, and further advancements of our development pipeline. We achieved quarterly revenue of $207.6 million, up approximately 8% year-over-year and 13% sequentially. Growth was driven primarily by strong performance from BAQSIMI and Primatene MIST, supplemented by contributions from recently launched products. Gross margin decreased during the quarter, primarily driven by the impact of lower net pricing on certain products and higher manufacturing expenses, including costs associated with the remediation efforts at our IMS manufacturing facility. Bill will provide additional detail on these factors as well as the year-over-year earnings comparison in the financial review. Our strategy remains focused on three complementary growth priorities. First, maximizing the growth of BAQSIMI and Primatene MIST while expanding our differentiated commercial portfolio. Second, advancing our pipeline of complex generics and biosimilars. And third, progressing our proprietary development program. Our scientific, manufacturing, and commercial capabilities support each of these initiatives. I would like to provide an update on each, beginning with our commercial portfolio. BAQSIMI delivered record quarterly net sales of $58.8 million, representing growth of approximately 10% compared to the prior year's period. The increase was driven by higher unit volumes, partially offset by lower net pricing associated with commercial discounts and customer mix. During the quarter, the measures we implemented to address duplicate 340B discounts continued to produce results, further reducing their impact relative to the second quarter. We remain focused on driving prescription growth, expanding patient access, and executing our commercial strategy to maximize the long-term value of the franchise. Primatene MIST delivered record quarterly net sales of $31.5 million, an increase of approximately 9% compared to the prior year's period. Growth was driven by both the price increase implemented in the second quarter and higher unit volumes, with in-store unit sales increasing approximately 2.5% year-over-year. These results highlighted the strength of our commercial operation and our ability to successfully manage differentiated pharmaceutical products across multiple markets and distribution channels. More recent product launches also contributed meaningfully during the quarter. Specifically, ipratropium bromide, which launched in April, generated $6.6 million in sales, while teriparatide contributed $6.4 million. These launches supported overall portfolio growth and partially offset headwinds affecting certain established products, including glucagon injections.

    Frequently Asked Questions About AMPH

    When is Amphastar P's next earnings date?

    Amphastar P's next earnings report is expected for Feb 24, 2027.

    Did AMPH beat earnings estimates last quarter?

    Yes. Amphastar P reported EPS of $1.01 for the quarter ended Sep 30, 2026, above the $0.80 estimate, a 26.25% surprise.

    What EPS do analysts expect from AMPH next quarter?

    The consensus EPS estimate for Amphastar P for the quarter ending Dec 31, 2026 is $0.79 from 9 analysts, with estimates from $0.51 to $1.05.

    How often does AMPH beat earnings estimates?

    Amphastar P beat the EPS estimate in 5 of the last 8 quarters, with an average surprise of +5.67%.